---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-22-000016"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2022-12-20T23:59:59+00:00"
generated_at: "2026-06-21T01:31:58.640306+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports positive 24-week pemvidutide NAFLD trial: >75% liver fat reduction, 7.2% weight loss at 1.8 mg

## Summary
- At 1.8 mg dose, mean relative liver fat reduction 75.2%; 53.8% achieved normalization (≤5% LFC).
- Mean weight loss of 7.2% (placebo-adjusted 6.0%) in non-diabetic subjects at 1.8 mg dose.
- Significant ALT declines: ≥17 IU/L reduction in subjects with baseline ALT ≥30 IU/L across all doses.
- cT1 response (≥80 ms reduction) achieved in 75% (1.8 mg) and 100% (2.4 mg) of evaluated subjects.
- Pemvidutide well tolerated; 3 serious/severe AEs unrelated to drug; no significant ALT elevations.

## SEC filing metadata
- accession: 0001326190-22-000016
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2022-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619022000016/0001326190-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619022000016/alt-20221220x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-22-000016
- JSON: https://secwatch.observer/filing/0001326190-22-000016.json
- Plain text: https://secwatch.observer/filing/0001326190-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.